Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®
48-week Phase III data showed Cyltezo® and Humira® have similar efficacy, safety and immunogenicity in people with rheumatoid arthritis1 Patients who switched at week 24 from Humira® to Cy......